<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089438</url>
  </required_header>
  <id_info>
    <org_study_id>200A</org_study_id>
    <nct_id>NCT02089438</nct_id>
  </id_info>
  <brief_title>DPP-4 Inhibition, Incretins and Islet Function</brief_title>
  <acronym>CODI24</acronym>
  <official_title>Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and
      islet hormones. The study examines this in relation to breakfast, lunch and dinner over an
      entire 24h study period by the use of three different DPP-4 inhibitors and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-center study with a cross-over design to examine glycemia, incretin
      hormones and islet hormones over a 24h study period with standardized breakfast, lunch and
      dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>180 min</time_frame>
    <description>The area under the 180 min curves for plasma glucose after each meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulin and glucagon</measure>
    <time_frame>180 min</time_frame>
    <description>The area under the 180 min curves for plasma insulin and glucagon after each meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>180 min</time_frame>
    <description>The area under the 180 min curves for plasma GLP-1 and GIP after each meal</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ssaxagliptin is given before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>´Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin is given before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin is given before breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Saxagliptin (5 mg) is given before breakfast</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin (50mg) is given before breakfast and dinner</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin (100 mg) is given before breakfast</description>
    <arm_group_label>´Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Caucasian men or women with type 2 diabetes diagnosed according to ICD10 at time of
             inclusion

               -  Ongoing treatment with life style adjustment including diet and exercise regimen
                  together with metformin as oral antidiabetic . Metformin therapy should be stable
                  the last three months

               -  Age 40-75 years

               -  HbA1c 52-80 mmol/mol (inclusive)

               -  BMI: 20-40 kg/m2

               -  Written informed consent has been given

               -  Capability and willingness to participate in the whole study

        Exclusion Criteria:

          -  • Liver disease (K70-77 in ICD10) or liver enzymes three times above upper reference
             range

               -  Diabetic nephropathy (GFR &lt; 30 mL/min/1.73 m2 or albuminuria) or other causes of
                  renal disease

               -  Proliferative diabetic retinopathy

               -  Treatment with any glucose-lowering medication except metformin

               -  Previous myocardial infarction, coronary heart disease or instable angina
                  pectoris in the last 6 months.

               -  Symptomatic heart failure (NYHA class II-III)

               -  Previous surgery on the gastrointestinal tract

               -  Larger surgical intervention during the last 12 weeks

               -  Female subject who are pregnant or breast feeding

               -  Women of child bearing potential not using a highly effective method of birth
                  control

               -  Treatment with oral steroids, thiazide diuretics, digoxin or growth hormone

               -  Hypersensitivity to the active substances of to any of the excipients

               -  Participation in another study the last 4 weeks

               -  Smoker

               -  Paracetamol intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahrén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Department</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

